Effects of hydroxylated resveratrol and its analogues on oxidative stress in cancer cells – their antioxidant, pro-oxidant and cytotoxic activity
Marek Murias
Poznan University of Medical Sciences, Poland
: Forensic Toxicol Pharmacol 2015, 4:3
Abstract
Resveratrol and its higher hydroxylated analogues (HHRA) have been reported to possess a variety of biological properties including antioxidant as well as pro-oxidant activity. The antioxidant properties are assumed to enable these compounds to protect cells from oxidative damage, however pro-oxidant activity are held likely to be responsible for their cytotoxic or pro-apoptotic effects. In our studies the effects of resveratrol and HHRA were investigated in various cancer cell lines including breast and cervix cancer derived cells as well as T cell leukemia Jurkat cells. In our experiments several markers of oxidative stress and apoptosis-linked events were evaluated. Taken together, resuts of our experiments suggetsed that HHRA possesing ortho-hydroxy groups are stronger cytotoxic agents than compounds without such a structure. Although these compounds were unstable in our experimental systems, they exert strong cytotoxic effect, which may be connected with induction of oxidative stress in cancer cells. The effects of oxidative stress could be shown in our experiments e.g. by accelerated oxygen consumption, increased MDA level or decerased level of GSH. These events suggest formation of short-living, prooxidative, highly cytotoxic metabolites in cells incubated with HHRA possesing ortho-hydroxy groups. These effects were less intense when HHRA without ortho-hydroxy groups were used. It was suggested therefore that HHRA may be grouped, into molecules that can either form quinoid systems upon two electron oxidation (QFS) or are unable to form such a structure (NQFS). These compounds may be classified as quinone forming QFS, may be used as anticancer agents while, NQFS represented in this study, presented e.g. by resveratrol may be used mainly as antioxidants.
Biography
